Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
NCT06855277
This study is recruiting at 42 US sites in 26 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to determine whether [225Ac]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, plus androgen receptor pathway inhibitor (ARPI), improves the radiographic progression free survival (rPFS) compared to investigator's choice of standard of care (SOC) (ARPI change or taxane-based chemotherapy or [177Lu]Lu-PSMA-617 (AAA617)) in adult participants with PSMA-positive metastatic castration resistant prostate cancer (mCRPC) treated with another ARPI as last treatment and who have not been exposed to a taxane-containing chemotherapy…
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Prostate Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 to 100 years
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- Novartis Pharmaceuticals
- Last updated on ClinicalTrials.gov
- October 15, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 1
- Urology Centers Of Alabama Pc · Homewood, AL
Arizona · 1
- University of Arizona · Tucson, AZ
California · 3
- Univ Cali Irvine ALS Neuromuscular · Orange, CA
- Stanford University Medical Center · Palo Alto, CA
- Sansum Clinic · Santa Barbara, CA
Colorado · 1
- Rocky Mountain Cancer Centers · Denver, CO
Florida · 3
- Florida Cancer Specialists · Fort Myers, FL
- Baptist Health South · Miami, FL
- AdventHealth · Orlando, FL
Georgia · 1
- University Cancer and Blood Center LLC · Athens, GA
Illinois · 2
- Northwestern University · Chicago, IL
- University of Illinois Cancer Center at Chicago · Chicago, IL
Iowa · 1
- Univ Of Iowa Hospitals And Clinics · Iowa City, IA
Kansas · 1
- University of Kansas Hospital · Kansas City, KS
Louisiana · 1
- East Jefferson Hospital · Metairie, LA
Maine · 1
- New England Cancer Specialists · Scarborough, ME
Maryland · 1
- Johns Hopkins Hospital · Baltimore, MD
Massachusetts · 2
- Beth Israel Deaconess Med Center · Boston, MA
- Dana Farber Cancer Institute · Boston, MA
Michigan · 1
- Karmanos Cancer Institute · Detroit, MI
Missouri · 1
- Wash U School of Medicine · St Louis, MO
Nebraska · 1
- Nebraska Cancer Specialists · Omaha, NE
New Jersey · 2
- Astera Cancer Center · East Brunswick, NJ
- New Jersey Urology LLC · Voorhees Township, NJ
New Mexico · 1
- New Mexico Oncology Hematology · Albuquerque, NM
New York · 5
- Bassett Medical Center · Cooperstown, NY
- Weill Cornell Medicine NY-Presb · New York, NY
- University of Rochester Medical Ctr · Rochester, NY
- Associated Med Professionals of NY · Syracuse, NY
- Montefiore Medical Center · The Bronx, NY
Ohio · 2
- Urology Group - Solaris Network · Cincinnati, OH
- Central Ohio Urology Group · Gahanna, OH
South Carolina · 2
- MUSC Hollings Cancer Center · Charleston, SC
- Carolina Urologic Research Center · Myrtle Beach, SC
Tennessee · 1
- Tennessee Oncology PLLC · Chattanooga, TN
Texas · 3
- Urology Austin · Lakeway, TX
- Urology San Antonio · San Antonio, TX
- Woodlands Cancer Institute American Oncology Partners · The Woodlands, TX
Washington · 2
- Swedish Medical Center · Seattle, WA
- Northwest Medical Specialties · Tacoma, WA
West Virginia · 1
- West Virginia University Hospital · Morgantown, WV
Wisconsin · 1
- Medical College of Wisconsin · Milwaukee, WI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.